GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
Zacks.com on MSN15d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaGSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...
Two years after pulling Blenrep from the market, GSK is positioning for a relaunch. This time, the company says it’s coming ...
Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...
GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback